Chardan Capital Sticks to Their Hold Rating for Evelo Biosciences Inc (EVLO)

By Austin Angelo

Chardan Capital analyst Taylor Feehley reiterated a Hold rating on Evelo Biosciences Inc (EVLOResearch Report) today and set a price target of $10. The company’s shares opened today at $5.69, close to its 52-week low of $5.13.

According to TipRanks.com, Feehley is ranked 0 out of 5 stars with an average return of -36.9% and a 0.0% success rate. Feehley covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Kaleido Biosciences Inc, and Assembly Biosciences.

The the analyst consensus on Evelo Biosciences Inc is currently a Hold rating.

See today’s analyst top recommended stocks >>

Based on Evelo Biosciences Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $20.3 million. In comparison, last year the company had a GAAP net loss of $15.15 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Evelo Biosciences, Inc. operates as a clinical stage biotechnology company developing monoclonal microbials, a potential new modality of oral biologic medicines. Its product candidates are single strains of microbes, selected for defined pharmacological properties.